

Zydus Announces New Data Presentations at The Liver Meeting® 2022

- *Four Posters accepted at The Liver Meeting® 2022*
- *Two Posters are awarded the “AASLD Presidential Poster Of Distinction”*

Ahmedabad, India November 03, 2022

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global lifesciences company today announced that four abstracts on Saroglitazar Mg will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 – 8, 2022).

Presentation Details

- Title: "Saroglitazar Improves Atherogenic Risk in Patients with Nonalcoholic Fatty Liver Disease: Pooled Analysis from Randomized Controlled Trials" [Publication Number: 2598]
- Title: “Saroglitazar versus Vitamin E in patients with biopsy proven NASH: a randomised controlled trial” [Publication Number: 2390]
- Title: “Safety and efficacy of saroglitazar in potential voluntary live liver donors with mild to moderate hepatic steatosis. A single-centre experience” [Publication Number: 2509]
- Title: “Saroglitazar in Nonalcoholic Steatohepatitis patients-a speck of optimism” [Publication Number: 2396]

The Liver Meeting Digital Experience™ 2022 website has the full list of abstracts [<https://www.aasld.org/the-liver-meeting>].

About Saroglitazar in Primary Biliary Cholangitis (PBC) and Non-alcoholic Steatohepatitis (NASH)

Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trial in patients with Primary Biliary Cholangitis (PBC) and Phase 2b in patients with Non-alcoholic Steatohepatitis (NASH).



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878



Dedicated To Life

The USFDA has granted 'Orphan Drug Designation' and 'Fast Track Designation' to Saroglitazar Mg for PBC. The European Medicines Agency (EMA) has designated "Saroglitazar magnesium" with Orphan status for Treatment of Primary Biliary Cholangitis.

NASH is a chronic liver disease characterised by fat accumulation and inflammation in the liver, which can progress to liver cirrhosis, need for liver transplant or death. There are currently no drugs approved in the USA for treatment of NASH – a global unmet medical need.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878